3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Colorectal Neoplasms
19
Colonic Neoplasms
9
Pancreatic Neoplasms
8
Esophageal Neoplasms
7
Stomach Neoplasms
6
Rectal Neoplasms
5
Adenocarcinoma Of Esophagus
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Large B-Cell, Diffuse
4
Cholangiocarcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Endometrial Neoplasms
3
Adenocarcinoma
3
Recurrence
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Bowel Adenocarcinoma
1
Prostatic Neoplasms
1
Interventions
venetoclax
5
Rituximab
5
Cyclophosphamide
4
Whole-Body Irradiation
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
zanubrutinib
2
pirtobrutinib
2
fludarabine phosphate
2
fludarabine
2
Specimen Handling
2
Prednisone
2
Mycophenolic Acid
2
Lenalidomide
2
CT-P10
2
Biopsy
2
treosulfan
1
pomalidomide
1
obinutuzumab
1
ibrutinib
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Sirolimus
1
R-CHOP protocol
1
Peripheral Blood Stem Cell Transplantation
1
Oxaliplatin
1
Methotrexate
1
Melphalan
1
Maintenance
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
Oxaliplatin
×
30 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled